Cepilimab is a novel PD-1 targeting monoclonal antibody with activity in squamous cell carcinoma of the skin
As reported at the ASCO 2018 meeting in Chicago, Migden et al report on athe results of the PD-1 targeting monoclonal antibody cemiplimab. was testing in a phase 1/2 clinical trial in patients with locally advanced and metastatic cutaneous squamous cell carcinoma of the skin. 26 patients in the phase 1 and 59 patients in the phase 2 trial were evaluated. All patients received 3mg/kg every 2 weeks. ORR was seen in 50% in the phase 1 and 47% in phase 2. 57% of patients had a response that lasted for more than 6 months. Fatigue was the most common adverse event reported in 27%,
News From PSMG
The latest news at Pacific Shores Medical Group
Disclaimer: This site is not designed to and does not provide medical advice, professional diagnosis, opinion, treatment or services to you or to any other individual. Through this site and linkages to other sites, Pacific Shores Medical Group provides general information for educational purposes only. The information provided in this site, or through linkages to other sites, is not a substitute for medical or professional care, and you should not use the information in place of a visit, call consultation or the advice of your physician or other healthcare provider. Pacific Shores Medical Group is not liable or responsible for any advice, course of treatment, diagnosis or any other information, services or product you obtain through this site.